08/03/22 8:15 AMNasdaq : EDSA conferenceslow floatEdesa Biotech to Participate at the Upcoming BTIG Biotech ConferenceEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held inRHEA-AIneutral
07/11/22 8:30 AMNasdaq : EDSA conferenceslow floatEdesa Biotech to Present at ARDS Drug Development SummitEdesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development SummitRHEA-AIneutral
05/24/22 7:55 AMNasdaq : EDSA clinical triallow floatEdesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS StudyEdesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Phase 2/3RHEA-AInegative
05/19/22 4:30 PMNasdaq : EDSA conferenceslow floatEdesa Biotech to Present at H.C. Wainwright Global Investment ConferenceEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright GlobalRHEA-AIneutral
05/13/22 8:55 AMNasdaq : EDSA earningslow floatEdesa Biotech Reports Fiscal 2nd Quarter 2022 ResultsEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 and provided an update on its business. ForRHEA-AIpositive
04/28/22 7:45 AMNasdaq : EDSA low floatEdesa Biotech Reports Dermatitis Study Enrolling Faster than ExpectedEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatoryRHEA-AIneutral
03/29/22 9:00 AMNasdaq : EDSA managementlow floatEdesa Biotech Appoints Strategy Expert to Board of DirectorsEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors. "Ms. Chao's appointment to ourRHEA-AIneutral
03/24/22 4:30 PMNasdaq : EDSA offeringlow floatEdesa Biotech Announces Closing of $10.0 Million Registered Direct OfferingEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rulesRHEA-AIneutral
03/22/22 8:00 AMNasdaq : EDSA offeringlow floatEdesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor forRHEA-AIneutral
02/17/22 8:00 AMNasdaq : EDSA clinical triallow floatEdesa Biotech Reports Enrollment Milestone in Phase 3 ARDS StudyEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibodyRHEA-AIneutral